PTAR at ICU admission independently predicts 28-day mortality in cancer patients with sepsis in both the MIMIC-IV and Chinese cohorts, outperforming SOFA and INR. The 365-day mortality was validated only in the MIMIC-IV cohort, where PTAR demonstrated stronger predictive performance compared to INR and SOFA. Therefore, PTAR can serve as a complementary biomarker to be used in conjunction with existing clinical scoring systems and laboratory indicators, providing additional risk assessment information for cancer-sepsis.
Wang et al. (Wed,) studied this question.